Search

Displaying results 1901 - 1910 of 9667 in total
  1. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    It has also been withdrawn from the Canadian market.[A669,L43942]

  2. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … [A189063] Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies.

  3. Drug

    Etafedrine

    go.drugbank.com/drugs/DB11587
    Approved

    It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563]. … It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6].

  4. Indication

    Periarteritis nodosa

    go.drugbank.com/conditions/DBCOND0023002
    Drugs: Tetracosactide
    Synonyms: PAN - Polyarteritis nodosa
  5. Drug

    Beeswax

    go.drugbank.com/drugs/DB11600
    Approved

    It is also used as a coating in the manufacture of modified-release oral preparations … It consists primarily of myricyl palmitate, cerotic acid esters and some high-carbon paraffins.

  6. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863. … a small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation.

  7. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    It has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.

  8. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    It is used extensively as an antiviral or antineoplastic agent.

    Mixtures: Intron A - Kit (pws+diluent) 3000000iu/vial, Intron A - Kit (pws+diluent) 5000000iu/vial
  9. Drug

    Dalteparin

    go.drugbank.com/drugs/DB06779
    ApprovedInvestigational

    Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000.

  10. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.